Evaluation of a Novel Sodium Borocaptate-containing Unnatural Amino Acid As a Boron Delivery Agent for Neutron Capture Therapy of the F98 Rat Glioma

Overview

Journal Radiat Oncol

Publisher Biomed Central

Specialties Oncology
Radiology

Date 2017 Jan 25

PMID 28114947

Citations 21

Authors

Gen Futamura

Shinji Kawabata

Naosuke Nonoguchi

Ryo Hiramatsu

Taichiro Toho

Hiroki Tanaka

Shin-Ichiro Masunaga

Yoshihide Hattori

Mitsunori Kirihata

Koji Ono

Toshihiko Kuroiwa

Shin-Ichi Miyatake

Affiliations

Soon will be listed here.

Abstract

Background: Boron neutron capture therapy (BNCT) is a unique particle radiation therapy based on the nuclear capture reactions in boron-10. We developed a novel boron-10 containing sodium borocaptate (BSH) derivative, 1-amino-3-fluorocyclobutane-1-carboxylic acid (ACBC)-BSH. ACBC is a tumor selective synthetic amino acid. The purpose of this study was to assess the biodistribution of ACBC-BSH and its therapeutic efficacy following Boron Neutron Capture Therapy (BNCT) of the F98 rat glioma.

Methods: We evaluated the biodistribution of three boron-10 compounds, ACBC-BSH, BSH and boronophenylalanine (BPA), in vitro and in vivo, following intravenous (i.v.) administration and intratumoral (i.t.) convection-enhanced delivery (CED) in F98 rat glioma bearing rats. For BNCT studies, rats were stratified into five groups: untreated controls, neutron-irradiation controls, BNCT with BPA/i.v., BNCT with ACBC-BSH/CED, and BNCT concomitantly using BPA/i.v. and ACBC-BSH/CED.

Results: In vitro, ACBC-BSH attained higher cellular uptake F98 rat glioma cells compared with BSH. In vivo biodistribution studies following i.v. administration and i.t. CED of ACBC-BSH attained significantly higher boron concentrations than that of BSH, but much lower than that of BPA. However, following convection enhanced delivery (CED), ACBC-BSH attained significantly higher tumor concentrations than BPA. The i.t. boron-10 concentrations were almost equal between the ACBC-BSH/CED group and BPA/i.v. group of rats. The tumor/brain boron-10 concentration ratio was higher with ACBC-BSH/CED than that of BPA/i.v. group. Based on these data, BNCT studies were carried out in F98 glioma bearing rats using BPA/i.v. and ACBC-BSH/CED as the delivery agents. The corresponding mean survival times were 37.4 ± 2.6d and 44.3 ± 8.0d, respectively, and although modest, these differences were statistically significant.

Conclusions: Our findings suggest that further studies are warranted to evaluate ACBC-BSH/CED as a boron delivery agent.

Citing Articles

Synthesis of New Promising BNCT Agents Based on Conjugates of -Dodecaborate Anion and Aliphatic Diamino Acids.

Ryabchikova M, Nelyubin A, Klyukin I, Selivanov N, Bykov A, Kubasov A Int J Mol Sci. 2025; 26(1.

PMID: 39795927 PMC: 11719580. DOI: 10.3390/ijms26010068.

Preparation and cell imaging of a nido-carborane fluorescent complex based on multi-component polymerization.

Ouyang H, Wang Z, Liu M PLoS One. 2024; 19(12):e0313661.

PMID: 39666694 PMC: 11637401. DOI: 10.1371/journal.pone.0313661.

Comparative Study of Cytotoxicity and Accumulation of Boron and Lithium-Containing Drugs in Skin Melanoma Cells In Vitro.

Kasatova A, Razumov I, Taskaev S, Taskaeva I Bull Exp Biol Med. 2024; 177(6):736-740.

PMID: 39441439 DOI: 10.1007/s10517-024-06260-3.

Peptide Conjugated Boron Neutron Capture Therapy for Enhanced Tumor Targeting.

Jyothi V, Kommineni N Nanotheranostics. 2024; 8(4):458-472.

PMID: 38961887 PMC: 11217788. DOI: 10.7150/ntno.95251.

Nonclinical pharmacodynamics of boron neutron capture therapy using direct intratumoral administration of a folate receptor targeting novel boron carrier.

Tsujino K, Kashiwagi H, Nishimura K, Fujikawa Y, Kayama R, Fukuo Y Neurooncol Adv. 2024; 6(1):vdae062.

PMID: 38770220 PMC: 11102930. DOI: 10.1093/noajnl/vdae062.

References

Kabalka G, Shaikh A, Barth R, Huo T, Yang W, Gordnier P . Boronated unnatural cyclic amino acids as potential delivery agents for neutron capture therapy. Appl Radiat Isot. 2011; 69(12):1778-81. PMC: 3135783. DOI: 10.1016/j.apradiso.2011.03.035. View

Barth R, Yang W, Rotaru J, Moeschberger M, JOEL D, Nawrocky M . Boron neutron capture therapy of brain tumors: enhanced survival following intracarotid injection of either sodium borocaptate or boronophenylalanine with or without blood-brain barrier disruption. Cancer Res. 1997; 57(6):1129-36. View

Yang W, Huo T, Barth R, Gupta N, Weldon M, Grecula J . Convection enhanced delivery of carboplatin in combination with radiotherapy for the treatment of brain tumors. J Neurooncol. 2010; 101(3):379-90. PMC: 4492111. DOI: 10.1007/s11060-010-0272-z. View

Mardor Y, Rahav O, Zauberman Y, Lidar Z, Ocherashvilli A, Daniels D . Convection-enhanced drug delivery: increased efficacy and magnetic resonance image monitoring. Cancer Res. 2005; 65(15):6858-63. DOI: 10.1158/0008-5472.CAN-05-0161. View

Barth R, Yang W, Huo T, Riley K, Binns P, Grecula J . Comparison of intracerebral delivery of carboplatin and photon irradiation with an optimized regimen for boron neutron capture therapy of the F98 rat glioma. Appl Radiat Isot. 2011; 69(12):1813-6. DOI: 10.1016/j.apradiso.2011.03.019. View

Yang W, Barth R, Adams D, Ciesielski M, Fenstermaker R, Shukla S . Convection-enhanced delivery of boronated epidermal growth factor for molecular targeting of EGF receptor-positive gliomas. Cancer Res. 2002; 62(22):6552-8. View

Hattori Y, Kusaka S, Mukumoto M, Ishimura M, Ohta Y, Takenaka H . Synthesis and in vitro evaluation of thiododecaborated α, α- cycloalkylamino acids for the treatment of malignant brain tumors by boron neutron capture therapy. Amino Acids. 2014; 46(12):2715-20. DOI: 10.1007/s00726-014-1829-5. View

Kimler B . The 9L rat brain tumor model for pre-clinical investigation of radiation-chemotherapy interactions. J Neurooncol. 1994; 20(2):103-9. DOI: 10.1007/BF01052721. View

Kawabata S, Miyatake S, Hiramatsu R, Hirota Y, Miyata S, Takekita Y . Phase II clinical study of boron neutron capture therapy combined with X-ray radiotherapy/temozolomide in patients with newly diagnosed glioblastoma multiforme--study design and current status report. Appl Radiat Isot. 2011; 69(12):1796-9. DOI: 10.1016/j.apradiso.2011.03.014. View

10.

Yamatomo N, Iwagami T, Kato I, Masunaga S, Sakurai Y, Iwai S . Sonoporation as an enhancing method for boron neutron capture therapy for squamous cell carcinomas. Radiat Oncol. 2013; 8:280. PMC: 3904744. DOI: 10.1186/1748-717X-8-280. View

11.

Shoup T, Olson J, Hoffman J, Votaw J, Eshima D, Eshima L . Synthesis and evaluation of [18F]1-amino-3-fluorocyclobutane-1-carboxylic acid to image brain tumors. J Nucl Med. 1999; 40(2):331-8. View

12.

Kawabata S, Miyatake S, Kuroiwa T, Yokoyama K, Doi A, Iida K . Boron neutron capture therapy for newly diagnosed glioblastoma. J Radiat Res. 2008; 50(1):51-60. DOI: 10.1269/jrr.08043. View

13.

Coderre J, Makar M, Micca P, Nawrocky M, Liu H, JOEL D . Derivations of relative biological effectiveness for the high-let radiations produced during boron neutron capture irradiations of the 9L rat gliosarcoma in vitro and in vivo. Int J Radiat Oncol Biol Phys. 1993; 27(5):1121-9. DOI: 10.1016/0360-3016(93)90533-2. View

14.

Ono K . An analysis of the structure of the compound biological effectiveness factor. J Radiat Res. 2016; 57 Suppl 1:i83-i89. PMC: 4990111. DOI: 10.1093/jrr/rrw022. View

15.

Barth R, Yang W, Rotaru J, Moeschberger M, Boesel C, SOLOWAY A . Boron neutron capture therapy of brain tumors: enhanced survival and cure following blood-brain barrier disruption and intracarotid injection of sodium borocaptate and boronophenylalanine. Int J Radiat Oncol Biol Phys. 2000; 47(1):209-18. DOI: 10.1016/s0360-3016(00)00421-1. View

16.

Barth R, Kabalka G, Yang W, Huo T, Nakkula R, Shaikh A . Evaluation of unnatural cyclic amino acids as boron delivery agents for treatment of melanomas and gliomas. Appl Radiat Isot. 2014; 88:38-42. PMC: 4049841. DOI: 10.1016/j.apradiso.2013.11.133. View

17.

Chandra S, Ahmad T, Barth R, Kabalka G . Quantitative evaluation of boron neutron capture therapy (BNCT) drugs for boron delivery and retention at subcellular-scale resolution in human glioblastoma cells with imaging secondary ion mass spectrometry (SIMS). J Microsc. 2014; 254(3):146-56. PMC: 4069218. DOI: 10.1111/jmi.12126. View

18.

Washburn L, Sun T, Anon J, Hayes R . Effect of structure on tumor specificity of alicyclic alpha-amino acids. Cancer Res. 1978; 38(8):2271-3. View

19.

Washburn L, Sun T, Byrd B, Hayes R, Butler T . 1-aminocyclobutane[11C]carboxylic acid, a potential tumor-seeking agent. J Nucl Med. 1979; 20(10):1055-61. View

20.

Hughes H, Brown F, Bull J, Goorley J, Little R, Liu L . MCNP5 for proton radiography. Radiat Prot Dosimetry. 2006; 116(1-4 Pt 2):109-12. DOI: 10.1093/rpd/nci109. View